Patent intelligence · US
US 11668704
Degradation preventing means for immunoassay reagent containing insoluble carrier particles
Degradation preventing means for immunoassay reagent containing insoluble carrier particles
Patent details — US 11668704
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 6, 2023
- Expiration
- Jun 1, 2043
- Applicant
- Fujikura Kasei Co., Ltd.
- Claims
- 6
- CPC classes
- A61K, A61K8/44
Quick answer
US 11668704 (Degradation preventing means for immunoassay reagent containing insoluble carrier particles) is held by Fujikura Kasei Co., Ltd.. Status: granted. Granted Jun 6, 2023. Expires Jun 1, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Fujikura Kasei Co., Ltd.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K8/44
More from Fujikura Kasei Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12377026
Dental adhesive material kit
granted -
US 12358210
Resin composition for stereolithography
granted -
US 12344691
Resin composition for stereolithography
granted -
US 12214061
Adhesive composition for dental use
granted -
US 12208148
Dental restorative curable composition
granted -
US 12145888
Zirconia molded body and pre-sintered body capable of being sintered in short time
granted -
US 12138325
Dental composition
granted
Frequently asked questions
What is US patent 11668704?
US 11668704 (Degradation preventing means for immunoassay reagent containing insoluble carrier particles) is held by Fujikura Kasei Co., Ltd.. Status: granted. Granted Jun 6, 2023. Expires Jun 1, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11668704?
Fujikura Kasei Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 132 pharmaceutical patents for this assignee.
When does US 11668704 expire?
Our index shows an expiration date of Jun 1, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.